Why atrial fibrillation is harder to treat in hypertrophic cardiomyopathy
Studies heart signals and imaging in adults with hypertrophic cardiomyopathy and atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Mechanisms of Atrial Pathoelectrophysiology in HCM
Key facts
- Where
- London, United KingdomSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07454135, who can take part
Where in United Kingdom
- Guy's and St Thomas' NHS Foundation TrustLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guy's and St Thomas' NHS Foundation Trust
- Trial code
- NCT07454135
- Record updated
- 11 September 2026
- Original description
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.Read full original descriptionShow less
Mechanisms of Atrial Pathoelectrophysiology in HCM
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.
Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.
The information from this study may help improve future treatments for people who have both HCM and AF.
Inclusion: Paroxysmal or persistent atrial fibrillation; Diagnosis of hypertrophic cardiomyopathy; Patient planning to proceed to atrial fibrillation ablation following clinical consultation; Age 18-80 years; Able and willing to provide written informed consent; Able and willing to comply with study follow up requirements.
Exclusion: Any disease limiting life expectancy to <1 year; Contraindication to MRI including renal dysfunction (eGFR<30ml/min); Any clinical contra-indication to ablation; Potential participant currently pregnant or breast feeding; Unable to understand verbal or written explanations given in English.